cas 73535-73-6|| where to buy 2-(6-Chloropyridazin-3-yl)-2-phenylacetonitrile

Название продукции:2-(6-Chloropyridazin-3-yl)-2-phenylacetonitrile

IUPAC Name:2-(6-chloropyridazin-3-yl)-2-phenylacetonitrile

Упаковочная единица	Доступно для заказа	Цена ($)
CM275205-250mg	in stock	ȋȋ
CM275205-1g	in stock	ƏǺœ
CM275205-5g	in stock	ƩǺȤ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 73535-73-6 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:73535-73-6; Молекулярная формула:C12H8ClN3; Точка плавления:-; Smiles-код:N#CC(C1=NN=C(Cl)C=C1)C2=CC=CC=C2; Плотность:

: Номер в каталоге:CM275205; Молекулярная масса:229.67; Точка кипения:; Номер Mdl:; Хранение:

: Pyridazines; Pyridazine, also known as o-diazobenzene, is a six-membered heterocyclic compound containing two nitrogen heteroatoms in the 1 and 2 positions with a special structure and a wide biological activity. Pyridazine is more and more popular in drug development, and a variety of pyridazine drugs have been developed and marketed. From the perspective of the therapeutic field, pyridazine drug molecules are mainly used for tumor treatment, but also involve in many therapeutic fields such as inflammation, hypertension and cardiovascular disease. With the increase and in-depth of research, pyridazine drugs will play more roles in the treatment of diseases.

: Neflamapimod; Dementia with Lewy Bodies (DLB) is a rapidly progressive neurodegenerative disorder with a significant aging population and unmet health need. Alterations in p38 mitogen-activated protein kinases (MAPKs) are found to contribute to the neurodegenerative process in Alzheimer's disease (AD) and related dementias.
CervoMed’s Neflamapimod (VX-745) is an oral, brain penetrant, small molecule inhibitor of the protein kinase p38α. It is designed to specifically target the mechanisms that cause dysfunction and degeneration of neurons in the basal forebrain cholinergic system. Neflamapimod has the potential of reversing synaptic dysfunction in the basal forebrain. The positive phase 2a data was published in Nature Communications, Neurology, and JPAD. Neflamapimod was granted Fast Track Designation by the FDA for DLB, and phase 2b enrollment was completed in June, 2024.